Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-81

I was reading your post closely thinking there was a word "not" missing. Sure enough you've picked up the same thing in your repost. Thanks for that it helps.

If you don't mind can you please provide a source for this -
"So all we really have to go by is the clear statement by Mesoblast that OTAT agree that the enhanced mechansim of action is reasonable".
Because I don't think that's exactly what Mesoblast says anywhere - I think you are accidentally changing something they have said (see below) to say something they haven't quite said - quite innocently but I think it might be important. Because I don't think the mechanisms of action changes.

I think MSB has reported that "OTAT indicated that Mesoblast's approach to address the outstanding CMC items is reasonable" (Key point 2 - 31 Dec 21 announcement) and

"OTAT indicated that the in vitro immunomodulatory activity Mesoblast intends to measure for potency is a reasonable critical quality attribute (CQA) for the product, and the relevance of this activity to clinical outcomes should be established" (Key point 3 - same announcement).

I think your post is excellent by the way - its just that things like missing "not" and statements that MSB have made a clear statement - that seem wrong to me and so need a source kind of make the rest harder to respond to with the respect it deserves -no irony used here.